Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease-Reference-Cited by-同舟云学术

Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease

Published:2019-01-21 Issue:3 Volume:142 Page:771-786
ISSN:0006-8950
Container-title:Brain
language:en
Short-container-title:

Author:

Park Jong-Chan¹,Han Sun-Ho¹²,Yi Dahyun³,Byun Min Soo³,Lee Jun Ho⁴,Jang Sukjin⁵,Ko Kang⁶,Jeon So Yeon⁴,Lee Yun-Sang⁷,Kim Yu Kyeong⁸,Lee Dong Young³⁴⁹,Mook-Jung Inhee¹²

Affiliation:

1. Department of Biochemistry and Biomedical Sciences, Seoul National University, College of Medicine, Seoul, Republic of Korea

2. Neuroscience Research Institute, Seoul National University, College of Medicine, Seoul, Republic of Korea

3. Institute of Human Behavioral Medicine, Medical Research Center Seoul National University, Seoul, Republic of Korea

4. Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea

5. Department of Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

6. Department of Geriatric Psychiatry, National Center for Mental Health, Seoul, Republic of Korea

7. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

8. Department of Nuclear Medicine, SMG–SNU Boramae Medical Center, Seoul, Republic of Korea

9. Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea

Funder

National Research Foundation of Korea

Korean government

NRF

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

Link

http://academic.oup.com/brain/article-pdf/142/3/771/27986626/awy347.pdf

Reference70 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Albert;Alzheimers Dement,2011

2. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice;Andreasen;Arch Neurol,2001

3. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease;Arai;Ann Neurol,1995

4. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data;Baker;Data Brief,2017

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moderation of Amyloid-β Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment;Journal of Alzheimer's Disease;2024-08-27

2. Disrupted brain functional connectivity as early signature in cognitively healthy individuals with pathological CSF amyloid/tau;Communications Biology;2024-08-23

3. Combined Serum Total Tau-Neurofilament Light Polypeptide Could be Used as Screening Biomarkers For Alzheimer’s Disease;2024-08-18

4. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology;Diagnostics;2024-08-10

5. Moderation of thyroid hormones for the relationship between amyloid and tau pathology;Alzheimer's Research & Therapy;2024-07-23